OM-85 BV for primary prevention of recurrent airway infections : a pilot randomized, double-blind, placebo-controlled study
OBJECTIVE: To compare the frequency of respiratory tract infections in children treated with OM-85 BV and placebo during the 3-month therapy period, and observation for a further 3 months after treatment.
METHODS: A randomized, double-blind, placebo-controlled trial was conducted with 54 children (6 months to 5 years old) with no past history of recurrent respiratory infections attending daycare center. Family members were instructed to administer one capsule per day for 10 consecutive days, for 3 months of OM-85 BV or placebo. Telephone interviews were conducted every 30 days.
RESULTS: There was no significant difference in the number of respiratory infections between the groups. The mean number of respiratory tract infection in the OM-85 BV Group in the first 3 months was 0.92±0.87, and in the Placebo Group was 0.74±1.02, and at 6 months it was 1.62±1.47 and 1.03±1.34, respectively.
CONCLUSION: OM-85 BV was not effective in the primary prevention of respiratory tract infections. Although most authors recommend the use of this immunostimulant in children with a history of recurrent respiratory infections, more studies are needed to define its usefulness in the primary prevention of respiratory infections in healthy children exposed to few risk factors.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
---|---|
Enthalten in: |
Einstein (Sao Paulo, Brazil) - 18(2020) vom: 02., Seite eAO5262 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Souza, Fátima Cleonice de [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adjuvants, Immunologic |
---|
Anmerkungen: |
Date Completed 30.03.2020 Date Revised 30.03.2020 published: Electronic-eCollection Citation Status MEDLINE |
---|
doi: |
10.31744/einstein_journal/2020AO5262 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM307216179 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM307216179 | ||
003 | DE-627 | ||
005 | 20231225125058.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.31744/einstein_journal/2020AO5262 |2 doi | |
028 | 5 | 2 | |a pubmed24n1024.xml |
035 | |a (DE-627)NLM307216179 | ||
035 | |a (NLM)32130328 | ||
035 | |a (PII)S1679-45082020000100240 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Souza, Fátima Cleonice de |e verfasserin |4 aut | |
245 | 1 | 0 | |a OM-85 BV for primary prevention of recurrent airway infections |b a pilot randomized, double-blind, placebo-controlled study |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 30.03.2020 | ||
500 | |a Date Revised 30.03.2020 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status MEDLINE | ||
520 | |a OBJECTIVE: To compare the frequency of respiratory tract infections in children treated with OM-85 BV and placebo during the 3-month therapy period, and observation for a further 3 months after treatment | ||
520 | |a METHODS: A randomized, double-blind, placebo-controlled trial was conducted with 54 children (6 months to 5 years old) with no past history of recurrent respiratory infections attending daycare center. Family members were instructed to administer one capsule per day for 10 consecutive days, for 3 months of OM-85 BV or placebo. Telephone interviews were conducted every 30 days | ||
520 | |a RESULTS: There was no significant difference in the number of respiratory infections between the groups. The mean number of respiratory tract infection in the OM-85 BV Group in the first 3 months was 0.92±0.87, and in the Placebo Group was 0.74±1.02, and at 6 months it was 1.62±1.47 and 1.03±1.34, respectively | ||
520 | |a CONCLUSION: OM-85 BV was not effective in the primary prevention of respiratory tract infections. Although most authors recommend the use of this immunostimulant in children with a history of recurrent respiratory infections, more studies are needed to define its usefulness in the primary prevention of respiratory infections in healthy children exposed to few risk factors | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
650 | 7 | |a Broncho-Vaxom |2 NLM | |
650 | 7 | |a Cell Extracts |2 NLM | |
650 | 7 | |a Tobacco Smoke Pollution |2 NLM | |
700 | 1 | |a Mocellin, Magáli |e verfasserin |4 aut | |
700 | 1 | |a Ongaratto, Renata |e verfasserin |4 aut | |
700 | 1 | |a Leitão, Lidiane Alves de Azeredo |e verfasserin |4 aut | |
700 | 1 | |a Friedrich, Frederico Orlando |e verfasserin |4 aut | |
700 | 1 | |a Silveira, Victória d'A |e verfasserin |4 aut | |
700 | 1 | |a Scotta, Marcelo Comerlato |e verfasserin |4 aut | |
700 | 1 | |a Pitrez, Paulo Márcio |e verfasserin |4 aut | |
700 | 1 | |a Pinto, Leonardo Araújo |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Einstein (Sao Paulo, Brazil) |d 2010 |g 18(2020) vom: 02., Seite eAO5262 |w (DE-627)NLM221652590 |x 2317-6385 |7 nnns |
773 | 1 | 8 | |g volume:18 |g year:2020 |g day:02 |g pages:eAO5262 |
856 | 4 | 0 | |u http://dx.doi.org/10.31744/einstein_journal/2020AO5262 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 18 |j 2020 |b 02 |h eAO5262 |